Roche Diagnostics Showcases Science-Driven Leadership and Innovation at ADLM 2025
Introduction
Roche Diagnostics is set to demonstrate its science-driven leadership and innovation at the 2025 Association for Diagnostics & Laboratory Medicine (ADLM) Scientific Meeting and Clinical Lab Expo, held July 28-31 in Chicago. The company's participation, under the theme "Lead With Us," emphasizes its commitment to fostering innovative partnerships, delivering better insights, faster support, and improved healthcare outcomes.
At the event, Roche will highlight its dedication to providing the right test at the right time, thereby empowering clinical decisions, simplifying operations, and transforming patient outcomes across the healthcare continuum. In an era of rapid scientific advancement, Roche leverages innovation and partnerships to deliver deeper insights and better outcomes, connecting more patients and labs with greater efficiency.
"Innovation, integration and partnership are the cornerstones of Roche's vision for the future of diagnostics," stated Brad Moore, president and CEO of Roche Diagnostics North America. "Our ADLM presence is about more than technology – it's about connecting science to people, delivering value where it matters most and working together to shape the next era of care."
Roche's offerings span from AI-powered digital transformation to proven assay performance, aiming to help laboratories achieve lasting success through evidence-based innovation and a focus on patient-centered care. Visitors can explore these solutions at Roche Diagnostics' Booth 1902.
Key Showcases and Innovations
Roche's presence at ADLM will feature a holistic approach to healthcare innovation, integrating powerful science with intelligent technologies. Key showcases include:
- The broadest menu on an integrated platform, including the Elecsys® Alzheimer's cerebrospinal fluid (CSF) assays for detecting amyloid pathology and supporting Alzheimer's disease diagnosis.
- The navify® digital solutions, designed to securely integrate data across care settings, connect the healthcare community, and accelerate access to innovation and insights, enabling confident healthcare decisions and driving operational, clinical, and financial value.
Expert-Led Medical Workshops
Roche is hosting two workshops led by industry experts:
Cardiovascular Risk Assessment and Lipoprotein(a): Closing Gaps in ASCVD Prevention
This workshop addresses Lipoprotein(a) (Lp(a)), a genetically inherited risk factor for Atherosclerotic Cardiovascular Disease (ASCVD), which remains under-recognized. It will explore critical gaps in awareness, testing, and risk stratification, focusing on identifying and managing individuals at high risk for cardiovascular disease.
Attendees will:
- Gain a deeper understanding of Lp(a)'s role in ASCVD and its implications for personalized care.
- Learn about Roche's FDA-cleared, commercially available Lp(a) Molarity Assay for standardized, actionable results.
- Explore how emerging Lp(a)-lowering therapies and diagnostics can support tailored cardiovascular risk management strategies.
Innovations in Cervical-Cancer Screening and Diagnosis
This session focuses on cervical cancer, one of the most preventable yet deadly cancers, particularly in underserved populations. It will cover the latest advancements in screening and diagnosis, including self-collection methods, updated clinical guidelines, and the role of technologies like extended HPV genotyping and home-based testing.
Attendees will:
- Review the current technology landscape for cervical-cancer screening and diagnosis.
- Explore updates to ASCCP and USPSTF guidelines and their implications for clinical practice.
- Consider strategies to expand access for under- or never-screened populations.
- Examine the potential role of home-collection in improving screening rates, including implementation and follow-up care challenges.
- Discuss the clinical utility and relevance of HPV extended genotyping.
Featured New Innovations at ADLM
Focusing on science-based leadership, operational simplicity, and patient-centric partnership, Roche will feature its newest innovations:
- The future cobas® Mass Spec solution: An end-to-end solution for clinical mass spectrometry testing with seamless integration into routine laboratories.
- The cobas® pure integrated solutions: Combines clinical chemistry, immunoassay, and Ion-Selective Electrode (ISE) diagnostic testing on a single platform for low- to mid-volume needs.
- The CCM Vertical: A flexible, modular system that optimizes lab space and integrates with existing cobas® connection modules.
- The cobas® liat system: Brings gold-standard PCR technology to the point of care, delivering results within 20 minutes for a range of CLIA-waived assays, focusing on respiratory and sexual health diagnostics.
- The cobas® eplex system: A rapid, syndromic molecular diagnostic solution offering test panels for respiratory and bloodstream infections, integrating the process from order to report.
- The cobas® 6800/8800 Systems v2: Designed to enhance usability, streamline efficiency, and support intuitive workflows, incorporating improvements based on customer feedback and usability testing.
- The LightCycler® PRO: A qPCR system designed for accuracy and flexibility in research and clinical diagnostic laboratories.
- The VENTANA® DP 600 slide scanner: A computer and imaging-based device for scanning, digitizing, storing, retrieving, and viewing digitized images of stained tissue specimens on glass slides.
Note: The cobas® 6800/8800 System Software 2.0 and new models are not yet available in the U.S. The future cobas® Mass Spec solution is not currently for sale in the United States.
About Roche
Founded in 1896 in Basel, Switzerland, Roche is a global leader in biotechnology and in-vitro diagnostics. The company is dedicated to scientific excellence in discovering and developing medicines and diagnostics to improve and save lives. Roche is a pioneer in personalized healthcare, aiming to transform healthcare delivery for greater impact. They partner with stakeholders, combining strengths in Diagnostics and Pharma with data insights.
Sustainability is integral to Roche's business. As a science-driven company, its contribution to society involves developing innovative medicines and diagnostics for healthier lives. Roche is committed to the Science Based Targets initiative and the Sustainable Markets Initiative to achieve net zero by 2045. Genentech, in the United States, is a wholly owned member of the Roche Group, and Roche is the majority shareholder in Chugai Pharmaceutical, Japan.
For Further Information
For more information on Roche's participation at ADLM 2025, visit ADLM.roche.com.
For general information about Roche, visit www.roche.com.
For media use and images, please visit the Roche Media Library.
Roche Diagnostics U.S. Media Relations:
Onsite Contacts at ADLM:
Jen Dial
jen.dial@roche.com
Phone: 1-463-867-0232
Amy Lynn
amy.lynn@roche.com
Phone: 1-317-750-7811
